| Beam Therapeutics is a biotechnology company. Co. is engaged in creating a class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases. Co.'s base editors have two principal components that are fused together to form a single protein: a CRISPR protein, bound to a guide RNA, that utilizes the DNA-targeting ability of CRISPR, but modified to not cause a double-stranded break; and a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. The BEAM YTD return is shown above.
The YTD Return on the BEAM YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BEAM YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BEAM YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.